Provention Bio Inc

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Provention Bio is a clinical-stage biopharmaceutical company dedicated to sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease. Their predict and prevent model is focused on developing novel therapeutic approaches that intervene before the target disease begins, re-appears, or progresses.  Provention Bio offers the potential to reduce the high morbidity, mortality, patient suffering, and escalating costs of chronic autoimmune and inflammatory diseases, such as type 1 diabetes (T1D), Crohn’s disease, ulcerative colitis, and emerging viral infections. They believe Provention’s business model, coupled with its expertise in translational medicine, immunology, and the design and execution of rapid go/no-go clinical trials, will enable them to in-license and efficiently partner both early-stage development assets and more advanced clinical-stage opportunities.

Adverum Biotechnologies

ArQule

Axsome Therapeutics

Zynerba Pharmaceuticals

These biotech stocks have at least quadrupled in just over six months this year.

5 Best Biotech Stocks of 2019 So Far

Provention Bio was able to show that those given PRV-031 were able to delay the onset of Type 1 Diabetes in a study known as "At Risk."

Provention Bio May Offer New Hope For People With Type 1 Diabetes With Latest Clinical Data

After decades of fairy tale wishes, we're now close to the reality of having a medicine that can simultaneously delay Type 1 diabetes on-set and prevent its occurrence.

Provention Bio: The Panacea For Diabetes

Abbott Labs

Eli Lilly

These three diabetes stocks have a lot going on this month.

3 Top Diabetes Stocks to Watch in June

Provention Bio, Inc. has canceled the public offering of common stock previously announced June 10 due to market conditions.

Provention Bio Cancels Secondary Offering, Shares Rally

Shares of Provention Bio Inc. PRVB, -1.66% surged 4.5% in premarket trade Thursday, after the biopharmaceutical company said it has terminated its planned public stock offering, citing current market conditions.

Provention Bio's stock surges after calling off public stock offering

Shares of Provention Bio, a New Jersey-based drug company that went public last year, more than tripled Monday after the company's experimental medicine appeared to delay onset of type 1 diabetes in a clinical trial.

Provention Bio shares more than triple on diabetes prevention study results

Provention Bio news about one of the company's drugs has PRVB stock heading higher Monday on positive results from a recent study.

Provention Bio News: Why PRVB Stock Is Skyrocketing Today

Shares of biotech Provention Bio Inc (NASDAQ: PRVB) are trading sharply higher Monday following publication of the results of a National Institutes of Health, or NIH,-sponsored study online in the New England Journal of Medicine as well as presentation of the same at the 79th Annual American Diabetes Association Meeting.

Provention Bio Jumps 300% After Pipeline Asset Shows Efficacy In Delaying Onset Of Diabetes In At-Risk Patients

As of late, it has definitely been a great time to be an investor in Provention Bio, Inc. (PRVB).

Provention Bio, Inc. (PRVB) Shares March Higher, Can It Continue? 

Provention Bio's (PRVB) CEO Ashleigh Palmer on Q4 2018 Results - Earnings Call Transcript

News for Provention Bio Inc Stock (PRVB)